Alembic Pharmaceuticals Q1 Reports 12% profit rise amid strong US Market sales
Alembic Pharmaceuticals Limited reported a strong performance in its Q1 results for the period ending June 30, 2024, primarily driven by robust sales in the US market. Alembic Pharmaceuticals has a strong presence in the US market, which is a key driver for its growth. In Q1 FY25, the company reported a 6% increase Read more: Alembic Pharmaceuticals Q1 Reports 12% profit rise amid strong US Market sales..